JACC:无创立体定向放射治疗高血压安全有效

2019-09-27 不详 网络

近期的临床随机对照研究显示基于导管的去肾神经术(RDN)在治疗高血压方面有良好的效果,本研究的目的旨在评估无创立体定向放射治疗(SBRT)作为RDN的一种的可行性、安全性和有效性。本研究对12只血压正常的小型猪的24条肾动脉进行了SBRT治疗,剂量分别为25、35和45Gy(每组n=4),另外4只小型猪作为对照。并对实验动物的基线、治疗后7天、1个月和3个月的血压、肾功能和血清去甲肾上腺素(NE)

近期的临床随机对照研究显示基于导管的去肾神经术(RDN)在治疗高血压方面有良好的效果,本研究的目的旨在评估无创立体定向放射治疗(SBRT)作为RDN的一种的可行性、安全性和有效性。

本研究对12只血压正常的小型猪的24条肾动脉进行了SBRT治疗,剂量分别为25、35和45Gy(每组n=4),另外4只小型猪作为对照。并对实验动物的基线、治疗后7天、1个月和3个月的血压、肾功能和血清去甲肾上腺素(NE)水平进行了检测。最后对12只小型猪成功进行了SBRT治疗,血压在各组之间无明显差异,但治疗后3个月血清和肾脏的NE水平在治疗组中明显更低。与对照组相比,SBRT可以明显增加神经损伤评分和降低酪氨酸羟化酶评分,而SBRT各组之间无明显差异。另外,CT和组织学分析结果显示接受35和45Gy剂量的动物的附带损害更明显,而25Gy组损伤最小。

研究结果显示,非侵入性的无创立体定向放射治疗作为去肾神经术的一种是可行且有效的,且在25Gy剂量时最安全。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854530, encodeId=6b95185453097, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 14 18:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986511, encodeId=3926198651154, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 19 21:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634369, encodeId=4f6a163436967, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Tue Jan 14 11:00:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769062, encodeId=59db1e690624f, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sun Oct 27 17:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326355, encodeId=acee13263552b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 29 00:00:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-02-14 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854530, encodeId=6b95185453097, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 14 18:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986511, encodeId=3926198651154, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 19 21:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634369, encodeId=4f6a163436967, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Tue Jan 14 11:00:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769062, encodeId=59db1e690624f, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sun Oct 27 17:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326355, encodeId=acee13263552b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 29 00:00:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854530, encodeId=6b95185453097, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 14 18:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986511, encodeId=3926198651154, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 19 21:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634369, encodeId=4f6a163436967, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Tue Jan 14 11:00:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769062, encodeId=59db1e690624f, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sun Oct 27 17:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326355, encodeId=acee13263552b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 29 00:00:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854530, encodeId=6b95185453097, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 14 18:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986511, encodeId=3926198651154, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 19 21:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634369, encodeId=4f6a163436967, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Tue Jan 14 11:00:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769062, encodeId=59db1e690624f, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sun Oct 27 17:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326355, encodeId=acee13263552b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 29 00:00:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-10-27 liao1632
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854530, encodeId=6b95185453097, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 14 18:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986511, encodeId=3926198651154, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 19 21:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634369, encodeId=4f6a163436967, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Tue Jan 14 11:00:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769062, encodeId=59db1e690624f, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sun Oct 27 17:00:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326355, encodeId=acee13263552b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 29 00:00:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]

相关资讯

盘点:JACC九月第三期研究一览

1.经导管二尖瓣置换术在严重二尖瓣钙化患者中的应用DOI: 10.1016/j.jacc.2019.07.069http://www.onlinejacc.org/content/74/11/1431在有严重二尖瓣环钙化(MAC)的情况下,二尖瓣反流(MR)的治疗具有挑战性。本研究的目的旨在评估经导管二尖瓣置换术在严重MAC患者中的疗效。本研究对9名严重MAC患者(平均年龄77±6岁,男性有5名)

JACC:Ibrutinib药物会出现严重的心脏毒性反应

Ibrutinib药物对于严重B淋巴细胞瘤的治疗来说是一场革命,然而近期的临床试验结果显示Ibrutinib会增加患者的死亡风险,其中心源性毒性被认为是罪魁祸首。本研究的目的旨在评估Ibrutinib药物相关的心血管毒性反应(CV-ADR)。本研究发现了303例Ibrutinib药物相关性死亡,Ibrutinib与更高的室上性心律失常(SVAs)相关(ROR: 23.1; 95% cl: 21.6

JACC:利伐沙班和阿司匹林联合治疗明显增加胃肠出血风险

对于冠心病和外周动脉疾病患者,相比于阿司匹林单独使用组患者,联合利伐沙班和阿司匹林可以降低主要不良心血管事件风险和死亡风险,并增加出血风险。本研究的目的旨在评估COMPASS临床试验中联合利伐沙班和阿司匹林与单独使用阿司匹林在出血事件方面的比较。在纳入的27395名患者中(平均年龄68岁,女性占22%),有18278名患者被随机分成利伐沙班和阿司匹林联合组和阿司匹林单独组,经过平均23个月时间的随

JACC:分期手术治疗新生儿法四患者的早期死亡风险明显更低

对于新生儿时期就有临床表现的法洛氏四联症(TOF)患者,最佳的治疗方法尚存在争议。本研究的目的旨在比较和评估完全和分期手术对新生儿TOF患者的疗效。本研究纳入分析了国家儿童健康数据库的在出生后30天内接受完全或分期手术治疗的TOF患者,主要终点事件是术后2年随访时间内发生死亡。最终共纳入了2363名TOF患者(1032名完全手术组和1331名分期手术组),共有239名患者死亡。在2年随访时间内,完

盘点:JACC九月第四期研究一览

1.利伐沙班和阿司匹林联合治疗明显增加胃肠出血风险DOI: 10.1016/j.jacc.2019.07.065http://www.onlinejacc.org/content/74/12/1519对于冠心病和外周动脉疾病患者,相比于阿司匹林单独使用组患者,联合利伐沙班和阿司匹林可以降低主要不良心血管事件风险和死亡风险,并增加出血风险。本研究的目的旨在评估COMPASS临床试验中联合利伐沙班

JACC:儿童时期二手烟的暴露增加了房颤的发生风险

吸烟可以增加房颤发生风险,近期的一项横断面研究显示父母吸烟同样是一个危险因素。本研究的目的旨在评估父母吸烟是否会增加子代房颤风险。 本研究纳入了2816名Framingham心脏研究队列中的子代,其中82%暴露与父母的吸烟状态中,父母吸烟每日增加一包,子代房颤的发生风险增高18%( [HR]: 1.18; 95% [CI]: 1.00-1.39; p = 0.04),另外,父母吸烟也是子代吸